Exact Mass: 679.2992
Exact Mass Matches: 679.2992
Found 53 metabolites which its exact mass value is equals to given mass value 679.2992,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
alpha-D-Glcp-(1?4)-[beta-D-Glcp-(1?3)]-beta-D-GalpNAc-(1?1)-ribitol
alpha-D-Glcp-(1?4)-[beta-D-Glcp-(1?3)]-beta-D-GalpNAc-(1?1)-ribitol
1beta-cis-cinnamoyl-4alpha-hydroxy-5alpha,7beta,11-triacetoxy-8beta-nicotinoyldihydroagarofuran|triptersinine E
1beta-cis-cinnamoyl-4alpha-hydroxy-5alpha,7beta,11-triacetoxy-8beta-nicotinoyldihydroagarofuran|triptersinine E
Cys Trp Trp Trp
(2S)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanoic acid
Trp Cys Trp Trp
(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanoic acid
Trp Trp Cys Trp
(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanoic acid
Trp Trp Trp Cys
(2R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanoic acid
dihydroergotamine mesylate
Dihydro Ergotamine Mesylate
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents D002491 - Central Nervous System Agents > D000700 - Analgesics Dihydroergotamine mesylate is an ergot alkaloid that can be used for the research of migraines[1][2][3].
5-methoxycarbonylpentyl 4,6-dideoxy-4-formamido-2-O-methyl-alpha-D-mannopyranosyl-(1->2)-4,6-dideoxy-4-formamido-alpha-D-mannopyranosyl-(1->3)-4,6-dideoxy-4-formamido-alpha-D-mannopyranoside
5-methoxycarbonylpentyl 4,6-dideoxy-4-formamido-2-O-methyl-alpha-D-mannopyranosyl-(1->2)-4,6-dideoxy-4-formamido-alpha-D-mannopyranosyl-(1->3)-4,6-dideoxy-4-formamido-alpha-D-mannopyranoside
Fibrinogen-Binding Peptide (TFA)
Fibrinogen-Binding Peptide (TFA)
Fibrinogen-Binding Peptide TFA (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide TFA binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin[1].
n-(1-oxo-1-{[(8e,10e,16z)-3,15,27-trihydroxy-5-methoxy-14,16-dimethyl-22-thia-2,24-diazatricyclo[18.6.1.0²¹,²⁵]heptacosa-1(27),2,6,8,10,16,20,23,25-nonaen-13-yl]oxy}propan-2-yl)cyclohexanecarboximidic acid
n-(1-oxo-1-{[(8e,10e,16z)-3,15,27-trihydroxy-5-methoxy-14,16-dimethyl-22-thia-2,24-diazatricyclo[18.6.1.0²¹,²⁵]heptacosa-1(27),2,6,8,10,16,20,23,25-nonaen-13-yl]oxy}propan-2-yl)cyclohexanecarboximidic acid
(1s,3r,5r,7s,8e,14e,16e,18e,20e,22s,24r,25s,26r)-22-{[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,26-trihydroxy-12,13-dimethyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0⁵,⁷]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid
(1s,3r,5r,7s,8e,14e,16e,18e,20e,22s,24r,25s,26r)-22-{[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,26-trihydroxy-12,13-dimethyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0⁵,⁷]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid
(2s,8s,15s,18r,22r,25s,26r)-8-benzyl-22-[(2s)-butan-2-yl]-10,17,24-trihydroxy-15,26-dimethyl-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,11,14(30),16,21(29),23-heptaen-7-one
(2s,8s,15s,18r,22r,25s,26r)-8-benzyl-22-[(2s)-butan-2-yl]-10,17,24-trihydroxy-15,26-dimethyl-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,11,14(30),16,21(29),23-heptaen-7-one
(2s,8s,15r,18r,22r,25s,26r)-8-benzyl-22-[(2s)-butan-2-yl]-10,17,24-trihydroxy-15,26-dimethyl-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,11,14(30),16,21(29),23-heptaen-7-one
(2s,8s,15r,18r,22r,25s,26r)-8-benzyl-22-[(2s)-butan-2-yl]-10,17,24-trihydroxy-15,26-dimethyl-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,11,14(30),16,21(29),23-heptaen-7-one
22-[(4-amino-3,5-dihydroxy-6-methyloxan-2-yl)oxy]-1,3,26-trihydroxy-12,13-dimethyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0⁵,⁷]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid
22-[(4-amino-3,5-dihydroxy-6-methyloxan-2-yl)oxy]-1,3,26-trihydroxy-12,13-dimethyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0⁵,⁷]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid
(1r,3s,5r,7r,8e,12r,13s,14e,16e,18e,20e,22r,24s,25r,26s)-22-{[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,26-trihydroxy-12,13-dimethyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0⁵,⁷]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid
(1r,3s,5r,7r,8e,12r,13s,14e,16e,18e,20e,22r,24s,25r,26s)-22-{[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,26-trihydroxy-12,13-dimethyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0⁵,⁷]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid
(2s,8s,15s,22s,26r)-8-benzyl-10,17,24-trihydroxy-15,26-dimethyl-22-(sec-butyl)-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,11,14(30),16,21(29),23-heptaen-7-one
(2s,8s,15s,22s,26r)-8-benzyl-10,17,24-trihydroxy-15,26-dimethyl-22-(sec-butyl)-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,11,14(30),16,21(29),23-heptaen-7-one
8-benzyl-10,17,24-trihydroxy-15,26-dimethyl-22-(sec-butyl)-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,11,14(30),16,21(29),23-heptaen-7-one
8-benzyl-10,17,24-trihydroxy-15,26-dimethyl-22-(sec-butyl)-27-oxa-13,20-dithia-6,9,16,23,28,29,30-heptaazapentacyclo[23.2.1.1¹¹,¹⁴.1¹⁸,²¹.0²,⁶]triaconta-1(28),9,11,14(30),16,21(29),23-heptaen-7-one
n-[(2r,3s,4s,5s,6r)-6-{[(1s,5r,7e,9r,10r,11s,12s,13s)-5-[(1e,3e)-6-[(1r,2s)-2-chlorocyclopropyl]hexa-1,3-dien-5-yn-1-yl]-1-hydroxy-9-methoxy-7,10,12-trimethyl-3-oxo-4,15-dioxabicyclo[9.3.1]pentadec-7-en-13-yl]oxy}-4-hydroxy-5-methoxy-2,4-dimethyloxan-3-yl]carboximidic acid
n-[(2r,3s,4s,5s,6r)-6-{[(1s,5r,7e,9r,10r,11s,12s,13s)-5-[(1e,3e)-6-[(1r,2s)-2-chlorocyclopropyl]hexa-1,3-dien-5-yn-1-yl]-1-hydroxy-9-methoxy-7,10,12-trimethyl-3-oxo-4,15-dioxabicyclo[9.3.1]pentadec-7-en-13-yl]oxy}-4-hydroxy-5-methoxy-2,4-dimethyloxan-3-yl]carboximidic acid
2-(2,3-dimethyloxiran-2-yl)-5,11-dihydroxy-10-{5-[(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-4,6-dimethyl-4-(methylamino)oxan-2-yl}-1-oxatetraphene-4,7,12-trione
2-(2,3-dimethyloxiran-2-yl)-5,11-dihydroxy-10-{5-[(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-4,6-dimethyl-4-(methylamino)oxan-2-yl}-1-oxatetraphene-4,7,12-trione
